Bacterial　skin　and　soft　tissue　infections　are　abundant　worldwide.　The　rise　in　the　incidence　of　multidrug-resistant　(MDR)　bacterial　infections　has　made　the　need　for　alternative　means　of　treatment　more　pressing.　We　herein　report　a　zinc　phthalocyanine　derivative,　pentalysine　beta-carbonylphthalocyanine　zinc　(ZnPc-(Lys)(5))　and　its　strong　capability　of　killing　nosocomial　MDR　bacteria,　including　MDR-Escherichia　coli　and　MDR-Acinetobacter　baumannii.　In　vitro　studies,　we　observed　that　ZnPc-(Lys)(5)　in　micromolar　concentrations　killed　above　MDR　bacteria　in　6　similar　to　6.5　log10　orders　with　only　5-min　illumination　of　red　light　at　a　dosage　of　12.75　J/cm(2)).　Further　in　vivo　studies　on　a　mouse　infection　model　demonstrated　that　ZnPc-(Lys)(5)　efficiently　inhibited　the　MDR　bacterial　growth　after　one-time　photodynamic　antibacterial　therapy　and,　interestingly,　significantly　accelerated　the　wound　healing.　Putting　together,　our　findings　establish　ZnPc-(Lys)(5)　as　a　potent　antimicrobial　candidate　for　the　clinical　test　on　localized　infection.